Tart cherry (Montmorency)
A juice with two small sleep trials and a real recovery signal, graded in the form the trials actually used.
C+
Evidence grade
C-
Worth it
$25-40/month
Typical cost
DoseThe sleep trial used two 8-ounce servings of tart cherry juice a day; recovery studies use juice or a concentrate equivalent, about a 30 ml concentrate shot once or twice daily. The juice form carries about a full serving of sugar per dose, which matters for the glucose-conscious reader. Capsule and extract doses have no comparable trial basis.
BasisTwo small sleep trials pointing the same way, recovery meta-analyses built from small trials, and no hard outcomes anywhere: that is a C+ file.
Tart cherry (Montmorency) is a sour cherry taken as juice or concentrate. We grade Tart cherry (Montmorency) C+ on evidence and C- for worth-it at about $25-40 per month.
What it does
Tart cherry (Montmorency) is a sour cherry taken as juice or concentrate. It carries small amounts of melatonin and tryptophan, plus the anthocyanins behind the recovery claim. The human trial data sit in juice and concentrate, not capsules, so this record is built on the juice form and says so wherever the capsule market implies otherwise.
What the research says
May improve sleep in small trials
Evidence: emerging. Two small trials point the same way: Pigeon et al. 2010 (n=15) found insomnia severity improved on tart cherry juice, and a small older-adult trial reported modest sleep-time gains. The plausible route is a small melatonin and tryptophan content. Effect sizes are modest and the samples are tiny.
May speed recovery and reduce muscle soreness
Evidence: emerging. Meta-analyses of small trials find small reductions in muscle soreness and faster strength recovery after hard exercise. The trials are short, the samples are small, and parts of the literature carry industry funding.
Two small sleep trials pointing the same way, recovery meta-analyses built from small trials, and no hard outcomes anywhere: that is a C+ file. The caps are the tiny samples, the short durations, industry funding in parts of the literature, and the sugar load that rides along with the studied form. A reasonable, low-risk food-form intervention with small effects grades at exactly that.
Is it worth it?
Evidence (C+) sits below the leaderboard floor, which caps the worth-it grade at C+; the derived value lands at C-, because the studied form is juice at two servings a day, about $33 a month, and the effects it buys are small. Derived from the October 2026 worth-it model.
Typical cost
$25-40/month
Common form, not a brand recommendation
Dosage context emerging
The sleep trial used two 8-ounce servings of tart cherry juice a day; recovery studies use juice or a concentrate equivalent, about a 30 ml concentrate shot once or twice daily. The juice form carries about a full serving of sugar per dose, which matters for the glucose-conscious reader. Capsule and extract doses have no comparable trial basis.
Worth-it leaderboard
Tart cherry (Montmorency) sits outside the worth-it top 20.
Tart cherry (Montmorency) sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Low risk as a food. The practical cautions are the sugar load in the juice form at trial doses, and the standing one for this record: capsule and extract claims borrow evidence the juice earned. Anyone managing blood sugar should count the juice as what it is, a sweetened fruit serving taken twice a day.
Longevity Lab Report
Tart cherry (Montmorency) news. Graded when it happens.
The grade on this page stays free. The email carries the news on tart cherry (montmorency): expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-27
- 2026-10-26|Graded in the weekly deep dive of 2026-10-26 (C+), from the Oct 25 queue intake. The record is built on the juice and concentrate trial data, per the intake ruling: the human evidence sits in the food form, not in capsules. Tart cherry was the second ungraded compound in the viral sleep product formula that triggered the 2026-10-25 queue ruling.
The week's longevity and biohacking news.
This grade for Tart cherry (Montmorency) rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.